Regarding biologics, mepolizumab, an anti-IL-5 mAb recently approved for HES without an identifiable secondary non hematologic cause, resulted in good control of most HES manifestations; however, reported skin outcomes are conflicting (169). The gene discussed is IL5; the disease is hypereosinophilic syndrome.